Clinical trials: Secondary Hyperparathyroidism
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior…
- Trial name
- NCT07890584
- Testing
- PLS240, Standard of Care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pathalys Pharma
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Hyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients
This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut…
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Chronic Kidney Diseases
- Trial name
- NCT07820150
- Volunteers
- 130 people
- Sponsor
- Assiut University
Secondary Hyperparathyroidism
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to < 18 years of age, with chronic…
- Trial name
- NCT03969329
- Testing
- Etelcalcetide
- Where
- 23 sites in Belgium, Czechia and 10 more
- Volunteers
- 24 people
- Sponsor
- Amgen
CKD Stage 3, CKD Stage 4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D…
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Trial name
- NCT07494045
- Testing
- CTAP101
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- OPKO Health, Inc.
End-Stage Kidney Disease (ESKD), Cardiovascular Disease
Cardiovascular Mortality Prediction in Maintenance Hemodialysis Patients
This prospective, single-center observational cohort study evaluates cardiovascular mortality risk in adults receiving maintenance hemodialysis.
- Conditions
- End-Stage Kidney Disease (ESKD), Cardiovascular Disease, Secondary Hyperparathyroidism (SHPT)
- Trial name
- NCT07769190
- Testing
- One-Year Serum Phosphate Target Achievement Rate, Parathyroidectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Huashan Hospital
Hemodialysis Subjects With Secondary Hyperparathyroidism
A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] MT1013.
- Trial name
- NCT07284043
- Testing
- [14C] MT1013/MT1013 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism…
- Trial name
- NCT06690242
- Testing
- MT1013, Etelcalcetide Hydrochloride
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism-Chronic Kidney Disease
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
Primary Objective: Evaluated the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH). Secondary Objectives: Evaluated the safety profile of Hectorol® capsules versus Rocaltrol®…
- Trial name
- NCT02859896
- Testing
- Doxercalciferol (GZ427397), Calcitriol
- Where
- 23 sites in United States, Chile
- Volunteers
- 21 people
- Sponsor
- Sanofi
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal…
- Trial name
- NCT04064827
- Testing
- Paricalcitol
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 2 people
- Sponsor
- AbbVie
Renal Osteodystrophy, Chronic Kidney Diseases
Precision Medicine Approaches to Renal Osteodystrophy
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease…
- Conditions
- Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder
- Trial name
- PMaROD (NCT05880914)
- Testing
- miRNAseq analysis, Standard treatment for bone disorder
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thomas Nickolas
Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism
Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia…
- Trial name
- Cin-ca (NCT07007338)
- Testing
- Supplementary blood samples and urines samples
- Where
- 7 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.
- Trial name
- NCT06236295
- Testing
- SHR6508
- Where
- China
- Volunteers
- 303 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Parathyroid Tumor, Primary Hyperparathyroidism
Parathyroid Tumor Clonal Status
To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will…
- Conditions
- Parathyroid Tumor, Primary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT), Tertiary Hyperparathyroidism
- Trial name
- NCT05997810
- Where
- United States
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Secondary Hyperparathyroidism
A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] SHR6508.
- Trial name
- NCT06877247
- Testing
- [14C] SHR6508 Injection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism, Chronic Kidney Disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Trial name
- NCT03633708
- Testing
- Etelcalcetide, Standard of Care
- Where
- 43 sites in United States, Argentina and 8 more
- Volunteers
- 56 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
A multicenter, Phase II, randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD), as well as single-arm clinical study evaluating the long-term efficacy and safety of MT1013 in hemodialysis…
- Trial name
- NCT06747247
- Testing
- Long-term Dosing Cohort, Single ascending doses of MT1013, Multiple ascending doses of MT1013
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism
The Trial of SHR6508 in Secondary Hyperparathyroidism
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
- Trial name
- NCT06434961
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active…
- Trial name
- NCT07122401
- Testing
- MT1013, Cinacalcet
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-1 (NCT05832931)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 362 people
- Sponsor
- Pathalys Pharma